• 1
    Daling JR,Madeleine MM,Schwarts SM, et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002; 84: 263270.
  • 2
    Hildesheim A,Han CL,Brinton LA, et al. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancers: results from a seroepidemiological case-control study. Obstet Gynecol. 1997; 90: 748754.
  • 3
    Walboomers J,Jacobs M,Manos M, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 1219.
  • 4
    Bosch FX,Manos MM,Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a world wide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 779780.
  • 5
    Singh GK,Miller BA,Hankey BF,Edwards BK. Persistent area socioeconomic disparities in US incidence of cervical cancer, mortality, stage, and survival, 1975-2000. Cancer. 2004; 101: 10511057.
  • 6
    Kosary CL. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-1987 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol. 1994; 10: 3146.
  • 7
    Saraiya M,Ahmed F,Krishnan S,Richards TB,Unger ER,Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007; 109: 360370.
  • 8
    Patel DA,Barnholtz-Sloan JS,Patel MK,Malone JMJr,Chuba PJ,Schwartz K. A population-based study of racial and ethnic differences in survival among women with invasive cervical cancer: analysis of Surveillance, Epidemiology, and End Results data. Gynecol Oncol. 2005; 97: 550558.
  • 9
    Howe HL,Wu X,Ries LAG, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among US Hispanic/Latino populations. Cancer. 2006; 107: 17111742.
  • 10
    Wang SS,Sherman ME,Hildesheim A,Lacey JVJr,Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004; 100: 10351044.
  • 11
    Trimble EL,Harlan LC,Clegg LX. Untreated cervical cancer in the United States. Gynecol Oncol. 2005; 96: 271277.
  • 12
    Goldie SJ,Grima D,Kohli M,Wright TC,Weinstein M,Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int J Cancer. 2003; 106: 896904.
  • 13
    Barnabas RV,Laukkanen P,Koskela P,Kontula O,Lehtinen M,Garnett GP. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modeling analyses. PLoS Med [serial online]. 2006; 3: e138.
  • 14
    Shi L,Sings HL,Bryan JT, et al. GARDASIL®: prophylactic human papillomavirus vaccine development—from bench top to bed-side. Clin Pharmacol Ther. 2007; 81: 259264.
  • 15
    Quinn MA,Benedet JL,Odicino F, et al. Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( suppl 1): S43S103.
  • 16
    Beller U,Quinn MA,Benedet JL, et al. Carcinoma of the vulva. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( ):suppl 1 S7- S27.
  • 17
    Beller U,Benedet JL,Creasman WT, et al. Carcinoma of the vagina. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006; 95( suppl 1): S29S42.
  • 18
    National Cancer Institute. PDQ Adult Treatment Summaries. Available at: Accessed October 14, 2007.
  • 19
    Eifel PJ,Moughan J,Erickson B,Iarocci T,Grant D,Owen J. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2004; 60: 11441153.
  • 20
    Katz A,Eifel PJ,Moughan J,Owen JB,Mahon I,Hanks E. Socioeconomic characteristics of patients with squamous cell carcinoma of the uterine cervix treated with radiotherapy in the 1992-1994 Patterns of Care Study. Int J Radiat Oncol Biol Phys. 2000; 47: 443450.
  • 21
    Mundt AJ,Connell PP,Campbell T,Hwang JH,Rotmensch J,Waggoner S. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol. 1998; 71: 151158.
  • 22
    del Carmen MG,Montz FJ,Bristow RE,Bovicelli A,Cornelison T,Trimble E. Ethnic differences in patterns of care stage 1a and stage 1A cervical cancer: a SEER database study. Gyneocol Oncol. 1999; 75: 113117.
  • 23
    Buchler JW. Surveillance. In: RothmanKJ,GreenlandS, eds. Modern Epidemiology.2nd ed. Philadelphia: Lippincott-Raven Publishers; 1998: 435458.
  • 24
    National Cancer Institute. Surveillance, Epidemiology, and End Results Program. NIH Publication No. 05-4772. Bethesda, MD: National Cancer Institute; 2005.
  • 25
    Surveillance, Epidemiology, and End Results (SEER) Program. Incidence—SEER 17 Registries Limited-Use (released April 2007, based on the November 2006 submission). Bethesda, MD: National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program, Cancer Statistics Branch, 2007.
  • 26
    Watson M,Saraya M,Ahmed F, et al. Using population-based cancer registry data to assess the burden of cancer in the United States: overview of methods. Cancer. 2008; 113( 10 suppl): 28412854.
  • 27
    Commission on Cancer. Facility Oncology Registry Data Standards. Revised for 2007. Chicago, Ill: American College of Surgeons; 2007. Available at: Accessed October 24, 2007.
  • 28
    GreeneFL,PageDL,FlemingID, et al, eds. Cervix uteri. AJCC Cancer Staging Handbook,6th ed. Chap 28. New York: Springer-Verlag; 2002: 293305.
  • 29
    JohnsonCH, ed. SEER Program Coding and Staging Manual 2004. Publication No. 04-5581. Bethesda, MD: National Institutes of Health; 2004.
  • 30
    SAS Institute. SAS OnlineDoc® 9.1.2. Cary, NC: SAS Institute Inc.; 2004.
  • 31
    National Cancer Institute. Joinpoint Regression Program, Version 3.0. Bethesda, MD: Statistical Research and Applications Branch, National Cancer Institute; 2005. Available at: Accessed October 7, 2007.
  • 32
    Luke C,Nguyen AM,Heard A,Kenny B,Shorne L,Roder D. Benchmarking epidemiological characteristics of cervical cancer in advance of change in screening practice and commencement of vaccination. Aust N Z J Public Health. 2007; 31: 149154.
  • 33
    The NCCN Guideline Cervical Cancer. Clinical Practice Guidelines in Oncology. Version I. 2008. National Comprehensive Cancer Network, Inc. Available at: Accessed March 11, 2008.
  • 34
    Beckmann CRB,Ling FW,Laube DW,Smith RP,Barzansky BM,Herbert WNP. Vulvar and vaginal disease and neoplasia. In: Obstetrics and Gynecology, 4th ed. Chap 43. Hagerstown, MD: Lippincott Williams & Wilkins; 2002: 533567.
  • 35
    Babalola EO,Bharucha AE,Schleck CD,Gebhart JB,Zinsmeister AR,Melton LJ. Decreasing utilization of hysterectomy: a population-based study in Olmstead County, Minnesota, 1965-2002. Am J Obstet Gynecol. 2007; 196: 214.e1214.e7.
  • 36
    Jackson KS,Naik R. Pelvic floor dysfunction and radical hysterectomy. Int J Gynecol Cancer. 2006; 16: 354363.
  • 37
    Saraiya M,Lee NC,Blackman D,Smith MJ,Morrow B,McKenna MA. Self-reported Papanicolaou smears and hysterectomies among women in the United States. Obstet Gynecol. 2001; 98: 269278.
  • 38
    Hewitt M,Devesa SS,Breen N. Cervical cancer screening among US women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004; 39: 270278.
  • 39
    Powell LH,Meyer P,Weiss G, et al. Ethnic differences in past hysterectomy for benign conditions. Womens Health Issues. 2005; 15: 179186.
  • 40
    Phillips JM,Cohen MZ,Moses G. Breast cancer screening and African-American women: fear, fatalism, and silence. Oncol Nurs Forum. 1999; 26: 561571.
  • 41
    Hakim RB,Benedict MB,Merrick NJ. Quality of care for women undergoing a hysterectomy: effects of insurance and race/ethnicity. Am J Public Health. 2004; 94: 13991405.
  • 42
    Brooks SE,Ahn J,Mullins CD,Baquet CR,D'Andrea A. Healthcare cost and utilization project analysis of comorbid illness and complications for patients undergoing hysterectomy for endometrial carcinoma. Cancer. 2001; 92: 950958.
  • 43
    Becker ER,Spalding J,DuChane J,Horowitz IR. Inpatient surgical treatment patterns for patients with uterine fibroids in the United States, 1998-2002. J Natl Med Assoc. 2005; 97: 13361342.
  • 44
    Fetters MD,Lieberman RW,Abrahamse PH,Sanghvi RV,Sonnad SS. Cost-effectiveness of Pap smear screening for vaginal cancer after total hysterectomy for benign disease. J Low Genit Tract Dis. 2003; 7: 194202.
  • 45
    Brown ML,Riley GF,Schussler N,Etzioni R. Estimating healthcare cost from SEER-Medicare data. Med Care. 2002; 40( suppl IV): 104117.
  • 46
    Follen M,Richards-Kortum R. Emerging technologies and cervical cancer. J Natl Cancer Inst. 2000; 92: 363365.
  • 47
    Insinga RP,Dasbach EJ,Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics. 2005; 23: 11071122.
  • 48
    Chesson HW,Blandford JM,Gift TL, et al. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004; 36: 1119.